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Sulfonated gallium(III) corroles are intensely fluorescent macrocy-
clic compounds that spontaneously assemble with carrier proteins
to undergo cell entry. We report in vivo imaging and therapeutic
efficacy of a tumor-targeted corrole noncovalently assembledwith
a heregulin-modified protein directed at the human epidermal
growth factor receptor (HER). Systemic delivery of this protein-
corrole complex results in tumor accumulation, which can be
visualized in vivo owing to intensely red corrole fluorescence.
Targeted delivery in vivo leads to tumor cell death while normal
tissue is spared. These findings contrast with the effects of doxo-
rubicin, which can elicit cardiac damage during therapy and re-
quired direct intratumoral injection to yield similar levels of tumor
shrinkage compared with the systemically delivered corrole. The
targeted complex ablated tumors at >5 times a lower dose than
untargeted systemic doxorubicin, and the corrole did not damage
heart tissue. Complexes remained intact in serum and the carrier
protein elicited no detectable immunogenicity. The sulfonated
gallium(III) corrole functions both for tumor detection and inter-
vention with safety and targeting advantages over standard che-
motherapeutic agents.
heregulin  human epidermal growth factor receptor  cancer 
in vivo imaging  porphyrinoids
Cancer is on track to overtake heart disease as the number 1cause of death worldwide next year. Chemotherapy has been
increasingly successful in treating this disease, but progress has
been slower than desired. Collaborative efforts of all relevant
disciplines will be required to enhance treatment efficacy and
facilitate quantitative dynamic monitoring (1). A case in point is
our potentially powerful technology combining both detection
and treatment in a single self-assembled complex between a
targeted cell penetration protein and a sulfonated gallium(III)
corrole. The intensely red corrole fluorescence enables complex
tracking in vivo.
The 2,17-bis-sulfonated corrole and its metal complexes share
similarities with porphyrins and related macrocycles that are
currently being explored for cancer therapy (2, 3), but their
recently revealed properties suggest distinct advantages over
other compounds. Specifically, these corroles are water soluble
(thus enabling facile use in physiological f luids), do not require
photoexcitation to elicit cytotoxicity (thus expanding the poten-
tial tissue depth and distance at which corrole-mediated therapy
may be administered), are unable to enter cells without the aid
of a carrier molecule (thus aiding the specificity of delivery), and
bind to cell-targeting proteins in a very tight, spontaneous and
noncovalent fashion (4, 5). Accordingly, we have explored the
possibility of assembling targeted corrole complexes with mod-
ified cell targeting ligands previously studied for tumor-targeted
cell penetration (6, 7). After screening several of our cell
targeted proteins against a panel of metallated and nonmetal-
lated corroles (6, 7), we selected the combination of a breast
cancer-targeted cell penetration protein (HerPBK10) and a
sulfonated gallium-metallated corrole (S2Ga), based on the
unique features of each component. S2Ga forms a tight assembly
with the carrier protein that resists high-speed centrifugation and
transfer to albumin, brightly f luoresces, and induces toxicity to
target cells after delivery and uptake by the carrier (6). Impor-
tantly, corrole cytotoxicity is best supported by a membrane
penetrating function, because nonpenetrating carriers such as
albumin did not enable sufficient cytotoxicity (6). This suggests
that sulfonated corroles entering cells via receptor-mediated
endocytosis must somehow escape the endosomal vesicle to
induce cytotoxicity (6). The protein used in these studies pro-
vides both the targeting and penetration required for effective
corrole delivery.
HerPBK10 contains the receptor-binding domain of
heregulin-B1B fused amino (N) terminally to a modified ade-
novirus (Ad) penton base capsid protein (7). The heregulin-
derived moiety has been used to direct nonviral and viral gene
delivery to HER2 cells in vitro (7, 8). The same ligand segment
produced as a recombinant fusion to green fluorescent protein
(GFP) shows preferential accumulation in HER2 tumors in
mice when delivered intravenously (Fig. S1). This ligand also
induces rapid endocytosis after receptor binding, thus enabling
entry of attached molecules into the target cell (9, 10). As
vesicle-entrapped ligands typically become degraded by lysoso-
mal enzymes or recycle back to the cell surface (which would
both reduce efficacy if used to deliver a therapeutic payload), the
penton base moiety of HerPBK10 contributes an endosomolytic
function to facilitate release of internalized particles into the
cytoplasm after uptake, thus enhancing therapeutic efficacy.
One important feature of HerPBK10 is that it binds and enters
HER2, but not HER2, human breast cancer cells in vitro (6,
7) (Fig. S2). HER2 breast tumors are characterized by an
amplification of the HER2 subunit and predict a poor prognosis,
resistance to chemotherapy, tumor recurrence, and high mor-
tality (11, 12). Normal mammary cells express low levels of
HER2 localized mainly in the cytoplasm, whereas HER2 am-
plification yields high levels displayed on the cell surface, and
enhanced mitogenic signaling, thus making the receptor a high-
profile landing pad for targeting. Monoclonal antibodies di-
rected against the extracellular domain of HER2 can influence
cancer growth, but have limitations in their ability to modulate
HER2 signaling (13, 14). Moreover, these antibodies can bind
tissues with normal HER2 levels, such as the myocardium, and
thus interfere with signaling for normal tissue maintenance.
When used in combination with conventional chemotherapeutic
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agents, such as doxorubicin, the adverse myocardial effects are
exacerbated, because doxorubicin alone also induces cardiac
damage (15–17). Although heregulin interacts directly with
HER3 or HER4 subunits, but not HER2 (18), ligand affinity is
greatly enhanced by HER2, which should enable therapies
targeted at the receptor heterodimer. Accordingly, such ligand-
directed therapies are likely to accumulate at HER2-amplified
heterodimers and avoid tissues displaying normal HER2 levels.
Here, we take advantage of HER ligand-receptor interaction
and endocytosis to deliver therapeutics into the cell and elicit cell
death from within, rather than trying to modulate signaling from
the cell surface. We rely on our previous findings showing that
noncovalent assemblies formed between HerPBK10 and sulfo-
nated corroles resist serum-induced destabilization and induce
targeted cell death in culture (6). We have focused our efforts on
developing targeted assemblies using S2Ga for 2 reasons: this
corrole was found to be the most toxic derivative (6) and its
intense fluorescence suggested that it could be very useful for
imaging purposes. Here, we report that a HER-targeted non-
covalent corrole assembly formed betweenHerPBK10 and S2Ga
(HerPBK10-S2Ga or HerGa) accumulates in HER2 cells and
induces tumor-targeted toxicity in a mixed cell population in
vitro as well as in vivo. Notably, we demonstrate the tumor-
targeting effect of HerPBK10 by whole animal imaging, and
report highly effective tumor-growth regression in mice with no
detectable effect on off-target tissues such as the heart and no
carrier protein immunogenicity.
Results
Corrole Fluorescence Enables Tracking of Tumor Targeting and Intra-
cellular Distribution. The ability to detect corrole fluorescence in
vivo allows not only the potential to detect tumors but also tracks
tumor targeted therapy in a live specimen. Here, we assess
HerGa targeting capacity in female nude mice bearing human
HER2 tumors on each flank. Mice received a single tail vein
injection of either HerGa or S2Ga alone, and the mice were
imaged in real time using a custom fluorescence bioimager (19).
Whereas S2Ga fluorescence exhibited a broad systemic distri-
bution throughout most of the mouse and appeared to be
excluded from the tumors, HerGa showed a preferential accu-
mulation in the tumors and a much lower distribution to
extratumoral areas compared with free S2Ga (Fig. 1A). A high
fluorescence signal in the tail region of both mice resulted from
some material inadvertently becoming deposited in the tail
muscle flanking the site of injection. Images acquired at sequen-
tial time points in real time after tail vein injection show that
HerGa accumulates rapidly at tumor sites within minutes after
administration (Fig. 1B). Corrole fluorescence detected at the
cellular level enables intracellular tracking of the complex in
target cells. Here, we can observe punctate corrole fluorescence
(Fig. 1C) transition over time to diffuse fluorescence (Fig. 1D)
during HerGa entry into live HER2 MDA-MB-435 human
cancer cells (suggestive of endocytic uptake followed by vesicle
leakage into the perinuclear cytosol), and cytosolic retention/
nuclear exclusion is visible up to at least 24 hr after HerGa
uptake in the same cells (Fig. 1E).
Targeted Corrole Ablates Tumor Cells in Vitro and in Vivo. We have
previously shown that HerGa specifically bound and entered
HER2 MDA-MB-435 but not HER2 MDA-MB-231 human
cancer cells in separate cell cultures, and inducedHER2 but not
HER2 cell death (6). Here, we introduce a further challenge by
testing the ability of HerGa to target HER2 cells in a mixed
culture of HER2 and HER2 cells. To identify each cell line in
coculture, the HER2 cells were tagged with a GFPmarker (Fig.
2 Top). We treated these mixed cultures daily with either HerGa
or with the equivalent concentration of S2Ga alone (0.5M) and
measured cell survival each day. Whereas HerGa reduced
HER2 but not HER2 cell counts (Fig. 2B), S2Ga had little
effect on either cell line (Fig. 2C). The cytotoxic positive control,
doxorubicin, was not as discriminatory between the 2 cell lines,
and in fact, was less effective on the HER2 cells (Fig. 2D).
HerPBK10 alone had no cytotoxic effect (Fig. 2A), indicating
that HerPBK10 contributes to targeting and is required for S2Ga
to elicit toxicity.
Ideally, targeting should afford the ability to administer a
therapeutic systemically and induce toxicity to tumor cells while
sparing normal tissue. To test this, we examined the therapeutic
efficacy of HerGa by measuring tumor volumes up to 25 days
after mice received daily tail vein injections of HerGa or controls
for 7 days. Tail vein injections were initiated once tumors
reached a size of 250–300 cubic mm (3–4 weeks after s.c.
tumor inoculation) (Fig. 3A). Whereas tumor growth was unaf-
fected in mice receiving saline or HerPBK10 alone, S2Ga
appeared to have a modest reducing effect on tumor growth.
Fig. 1. DetectionofHerGa in vivo targetingand intracellular trafficking. Live
animal imaging of corrole fluorescence after IV delivery of either free corrole
or targeted complex. (A)NudemicebearinghumanHER2 tumors (300 cubic
mm) received a single IV injection of either S2Ga or HerGa (15 nmoles with
respect to corrole dose) and were imaged at 2.5 hr postinjection using a
noninvasive small animal fluorescence imaging system (35). Schematic to the
left indicates the whole body and tumor orientation of the mice in the
fluorescent images. (B) Images capturing time course of corrole circulation in
mice after receiving HerGa as described in A. Arrows in both A and B point to
tumors. Corrole fluorescence is indicated by blue-red pseudocoloring with
fluorescence intensity represented according to the color bar on the right.
(C–E) Intracellular trafficking in live cells.MDA-MB-435 cellswere treatedwith
HerGa at 1 M final corrole concentration and live cells imaged by fluores-
cence microscopy at the indicated time points after treatment. (C and D)
High-resolution spinning disk micrographs (Perkin-Elmer/Improvision) show-
ing apparent vesicles and corrole fluorescence (pseudocolored green) distri-
bution in cytoplasm at 15 min (C) and 2 hr (D). (E) Micrograph of corrole
fluorescence (red) distribution in cytoplasm as captured by inverted fluores-
cencemicroscopy at up to 24hr after uptake. InC–E, fluorescence imageswere
overlaid on brightfield images. n, nucleus. (Scale bars, 10 m.)
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However, HerGa not only prevented tumor growth but appeared
to reduce the size of the tumors that were already established at
the time of treatment (Fig. 3B). Importantly, i.v. HerGa treat-
ment showed greater therapeutic efficacy at 5 times the lower
dose compared with free doxorubicin delivered systemically,
because 0.04 mg/kg Dox merely reduced tumor growth (Fig. 3C)
whereas 0.008 mg/kg HerGa not only inhibited tumor growth but
also elicited some shrinkage. Significant tumor shrinkage by
doxorubicin could only be observed if mice received relatively
high doses (2.5 mg/kg) injected intratumorally (Fig. 3C), thus
implying that systemic HerGa has similar effect to nearly 300
times higher doses of doxorubicin delivered intratumorally.
To examine whether off-target tissues such as the heart were
affected, mice were euthanized on the last day of tumor mea-
surement and tissues were harvested for histological examina-
tion. We compared hearts of treated mice to that of mice
receiving intratumoral injections of doxorubicin, which is known
to induce cardiotoxicity. Despite its local delivery, doxorubicin-
treated mice exhibited typical cardiomyopathy, including focal
degeneration and myofibrillar loss as observed elsewhere (20,
21), whereas mice receiving S2Ga or HerGa showed no signs of
myocardial damage, similar to saline-treated mice (Fig. 3D).
HerPBK10 alone also had no effect on myocardium histology.
Preimmune and Postimmune Serum Do Not Affect Targeting or
Stability. To address concerns regarding the use of an adenovirus
capsid protein-derived carrier for the corrole, we examined
whether HerPBK10 induced the formation of neutralizing an-
tibodies. A single inoculation of Ad can produce a long-lasting
humoral response in patients (22) and animals (23), and prevent
subsequent administration, thus reducing overall therapeutic
efficacy. Here, we tested the antibody formation potential of
HerPBK10 under the same conditions that produce an Ad
capsid-elicited humoral response (24). Immune competent
(C57BL/6) mice were inoculated with HerPBK10 at an equiva-
Fig. 2. Targeted cytotoxicity in a mixed culture of HER2 and HER2 human
cancer cells. Cell cultures containing 1:1 cell ratio of MDA-MB-435
(ErbB2,GFP):MDA-MB-231 (ErbB2,GFP) (Top) were treated with Her-
PBK10 alone (A), HerPBK10-S2Ga (B), S2Ga (C), or doxorubicin (Dox) (D) at 0.5
M final drug (corrole or Dox) concentration. HerPBK10 alone was added at
the equivalent concentration to the same protein in the complex. Cells were
treated daily for 1 week in complete (serum-containing) medium and cells
assessed at the indicated time points for GFP fluorescence (to determine
relative MDA-MB-231 number) and crystal violet staining (to determine total
cell number). Cell survivalwasdeterminedby calculating the relativedoubling
time (DT) of experimental (exp) cells normalizedby control (con) cells basedon
the crystal violet stains (total cells) and GFP fluorescence (MDA-MB-231 cells).
The DT of MDA-MB-435 was determined by subtracting the DT of MDA-MB-
231 from the total cell DT.
Fig. 3. Targeted tumorgrowth interventionbyHerGa. Effect of systemically-
delivered HerGa or individual components on tumor growth. Nude mice
bearing HER2 tumors received daily IV injections for 1 week of the indicated
reagentswhen the tumors reached 250–300 cubicmm (tumor inoculation and
treatment schedule depicted in A; SC, subcutaneous). Graph in B presents
tumor volumes measured before, during, and after treatment. Mice were
euthanizedat 25days after the last dayof treatment, and tissues harvested for
histological assessment.n 5–9 tumors per treatment group. (C) Comparative
doses of Dox delivered IV or intratumorally (IT) on tumor growth. Treatment
schedule is the same as in B. (D) Effect on myocardia of hearts harvested from
treated mice at the end of the experiments in B and C (‘‘Dox’’ hearts were
harvested from mice receiving Dox IT). Paraffin-fixed specimens were pro-
cessed for immunofluorescence against myosin and imaged at 60
magnification.
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lent HerGa therapeutic dose (0.05 mg/kg with regard to protein
dose) as well as a 10-fold higher dose (0.5 mg/kg). As a
comparison, mice were also inoculated with Ad5 at a dose
established elsewhere (24) to induce neutralizing antibody for-
mation (1.2 109 pfu permouse). Blood was collected frommice
before the initial antigen inoculation, followed by blood collec-
tions every 7 days up to 35 days after the initial inoculation,
whereas mice received a second inoculation of the same antigens
on day 21 to boost any existing immunity (Fig. 4A Upper,
timeline). Both doses of HerPBK10 produced no significant
induction of anti-HerPBK10 antibodies compared with un-
treated mice, whereas the dose of Ad5 triggered secretion of
antibodies that recognize HerPBK10 (Fig. 4A Lower). To assess
whether these antibodies actually prevent HerPBK10 binding to
target cells, receptor-ligand binding was measured by attach-
ment capacity of MDA-MB-435 cells to HerPBK10-coated
plates in immune serum. Compared with cells attached in
complete media, preimmune serum did not prevent, and even
modestly enhanced, cell attachment (P  0.03), and the level of
attachment in sera from either Ad5- or HerPBK10-treated mice
was comparable to that in preimmune serum (Fig. 4B). The
apparent increase in binding is unexpected and may be due to
composition differences between mouse serum and complete
media containing bovine serum. The ability of recombinant
heregulin ligand, Her, to inhibit cell attachment (P 0.01
compared with binding in preimmune serum, as determined by
a 2-tailed unpaired t test), verified that attachment takes place
via heregulin receptors (Fig. 4B). Overall, these findings indicate
that whereas Ad5 can generate antibodies against HerPBK10,
this is not enough to prevent binding of HerPBK10 to target cells.
Another in vivo concern regards the potential for premature
corrole release from the complex and its transfer to serum in
blood. Our previous studies have shown that corrole complexes
do not transfer the corrole to immobilized serum albumin in
vitro (6). To predict HerGa stability in vivo, we incubated the
complex up to 1 hr at 37 °C on immobilized human serum, then
removed the complex from the immobilized substrate and
assessed how much corrole is lost from the complex by compar-
ing the fluorescence after incubation on the immobilized sera
with the input fluorescence. We detected negligible loss of
corrole fluorescence from HerGa whereas S2Ga alone, which is
expected to bind readily to the serum proteins, exhibited con-
siderable loss to the immobilized serum (P0.03 compared with
incubation without serum) (Fig. 4C).
Discussion
Existing approaches to targeting therapeutic agents or drugs
require linking the compound to the targeted carrier by 1 or
more covalent bonds. Such chemical modifications complicate
preparation of the conjugate and entail high costs, and also can
compromise the potency of the drug and abrogate the activity or
specificity of the carrier molecule. Instead, a system in which the
therapeutic agent can be incorporated with a carrier and then
may be released into the target cell would be greatly preferred.
Earlier we demonstrated that this is possible by combining the
targeting and cell penetrating features of the HerPBK10 recom-
binant protein with corroles that can spontaneously assemble
with carrier molecules to form a new type of noncovalent
nanoparticle. Our previous in vitro investigations strongly indi-
cated that HER-targeted corrole particles specifically bind,
enter, and kill HER2 but not HER2 cells in separate cultures
(6). Here, we show that HER2 cells can even be targeted in a
mixed culture of HER2 and HER2 cells. The ability to track
our targeted particle in vivo by fluorescence has allowed us to
demonstrate that it localizes in HER2 tumors in vivo and elicits
tumor cell death. Importantly, established tumors undergo not
only growth prevention but also a reduction in volume, and these
desirable outcomes are achieved while sparing important tissues
Fig. 4. Neutralizing antibody induction and serum stability. (A) Immunocom-
petent (C57BL/6) mice received an initial s.c. inoculation of HerPBK10 protein
(0.05 or 0.5 mg/kg) or Ad5-GFP (1.2  109 pfu per mouse) followed by blood
collection scheduled every 7 days up to day 35 after the initial inoculation as
summarized by the time chart (Upper). On day 21, respective mice received a
second inoculation of each corresponding reagent. Sera isolated from bleeds
were assessed by ELISA for relative antibody titer produced against HerPBK10
(Lower). Arrows denote days of antigen inoculation. n  4 mice per treatment
group dose. (B) Effect of immune sera on target cell binding. Ligand-receptor
bindingwastestedbymeasuringthe levelofcellattachmenttoHerPBK10-coated
plates in immuneor preimmune serum collected frommice inA. Cells suspended
in either preimmune serum, immune serum from Ad5 or HerPBK10-inoculated
mice,orcompletemediacontaining10%bovineserumbutnomouseserumwere
incubatedonHerPBK10-coatedwells for1hrat37 °C, followedbyremovaloffree
cells and measurement of attached cells by crystal violet assay. The level of
receptor-specific bindingwas assessed on separate cells preincubatedwith com-
petitive inhibitor (Her). Un, untreated mice. *, P 0.01 compared with cells
attached in preimmune serum, as determined by the 2-tailed unpaired t test. (C)
Relative corrole retention by HerGa during incubation in human serum. Human
serum(OmegaScientific, Inc.)was immobilizedbyovernight incubationat4 °C in
96-well plates. Thenext day, thewellswerewashedwith PBS, andHerGaor S2Ga
alone (50 M final) were added to each well. After incubation at 37 °C for the
indicated time points, samples were removed from the wells and measured for
corrole fluorescence. Corrole retention or loss by the complex was assessed by
comparingthefluorescenceofpreserumandpostserumincubationsamples (RFU
424 nm excitation wavelength/620 nm emission wavelength of postincubation
sample/input). Fluorescence values are shown as a percentage of input fluores-
cence(offluorescenceofcomplexbeforeserumincubation).*,P0.03compared
with incubationwithoutserum.Significancesweredeterminedby2-tailedpaired
t tests.
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such as the heart, which can otherwise undergo adverse effects
from similar HER2-targeted treatments (15–17)
We have shown that corroles are superior to porphyrins and
related compounds for some applications. For example, Photo-
frin (a porphyrin derivative) is used as a photosensitizer, requir-
ing light of a specific wavelength to induce damage to tumor cells
after intratumoral accumulation (25). In contrast, we have found
(6) that corroles do not require photoexcitation to induce
cytotoxicity. Porphyrin derivatives have suboptimal absorption
for maximal tissue penetration, and are readily oxidized (26),
thus drastically limiting their use. Because photoexcitation is not
required for cell killing, corroles potentially could be used
effectively in a variety of in vivo sites. Whereas Photofrin
contains a complex mixture of ether- and ester-linked dimers and
higher oligomers, raising drug regulatory concerns, corroles can
be used as water-soluble molecules (27) for use under physio-
logical conditions.
Corroles also may have therapeutic and safety advantages over
currently used drugs such as doxorubicin and cisplatin, whose
mechanisms of action require nuclear entry to bind DNA and
inhibit replication (28). These drugs are nondiscriminatory and
can permeate nearly any cell, but aremost potent to dividing cells
(i.e., tumor tissue, but also bone marrow, hair, and gastrointes-
tinal tract epithelia). Nevertheless, damage to nondividing cells
is possible, as exemplified by the serious cardiotoxicity and
cytoskeletal damage incurred by doxorubicin on heart tissue (29,
30). In contrast, the inability of corroles to penetrate cell
membranes without a carrier protein can avoid such detrimental
side effects, should the corrole release prematurely from the
carrier before reaching a target cell. This is an unlikely possi-
bility, however, due to the high degree of binding stability to
endure ultrafiltration, HPLC, and nonexchange with serum
protein (5, 6). Our studies here further confirm that the targeted
complex retains integrity in human serum, localizes tumors in
vivo, and elicits tumor cell death while sparing healthy tissue
such as the heart.
Effect on the myocardium has become an important focus
regarding the use of HER2-targeted therapeutics in light of the
adverse cardiac effects that can be produced by inhibiting HER2
signaling, and that are exacerbated when used in conjunction
with doxorubicin (15–17). It is possible that by using the receptor
ligand for targeting rather than by using anti-HER2 antibodies
prevents homing in on tissues with normal HER2 levels, given
that ligand affinity for HER3 or HER4 are enhanced by ampli-
fication of HER2 (31–33). In this regard, it may be advantageous
to develop targeting agents with intermediate affinities and thus
reduce off-target effects while increasing accumulation at tissues
displaying amplified levels of the target receptor.
Our approach here is unique in its reliance on noncovalently
attached drugs that, through the use of a targeted endosomolytic
protein, may be released from endosomal vesicles inside a target
cell to induce toxicity. The amphiphilic nature of sulfonated
corroles makes this strategy possible by directing the drug to cells
targeted by the protein carrier and preventing nonspecific up-
take into cells without a protein carrier, thus avoiding detrimen-
tal effects to nontargeted cells. Preliminary investigations indi-
cate that traditional apoptosis does not substantially contribute
to cell death, whereas cytoskeletal disruption and mitochondrial
fragmentation delineate key events of corrole cytotoxicity. A
unique feature of the current approach is that the same com-
pound can be used both for imaging and therapeutic interven-
tion, opening new avenues for quantitative in vivo monitoring of
chemotherapeutic specificity, topology, dynamics, and effective-
ness (34), and thereby paving the way for discovery of even more
powerful multifunctional agents for use in the war on cancer.
Materials and Methods
Materials, Cells, and Animals. HerPBK10 protein was produced in and isolated
from a bacterial protein expression system as described in ref. 7. Gallium-
metallated sulfonated corrole was synthesized, reconstituted in PBS, and
quantified as described in ref. 6. MDA-MB-435 and MDA-MB-231 cells were
obtained from the National Cancer Institute and maintained at 37 °C in
DMEM, 10% FBS at 5% CO2. Athymic nude and C57BL/6 mice were obtained
from Charles River Laboratories, Inc. GFP-tagged cell lines were produced by
overnight incubation of cells plated in 6-well dishes with GFP-expressing
lentivirus vectors added at 1/3 and 1/9 dilution in 1mLof completemediawith
4 L of 1 mg/mL protamine sulfate. At 24 hr, cells were washed twice with
complete media, and monitored for green fluorescence. Cells were passaged
8 to 9 times to ensure removal of free virus particles before being used for
experimental purposes. All mice were euthanized following Institutional
Animal Care and Use Committee (IACUC)-approved procedures in accordance
with the institutional and national guide for the care and use of laboratory
animals.
ELISA. To determine HER2 levels on cell lines, cells plated in 96-well dishes (1
104 cells per well) 48 hr earlier were aspirated of medium and briefly washed
with PBS, then fixed in 4% PFA/PBS for 12 min at room temperature (RT),
followed by washing 3 times with PBS (250 L per well) before a 1 hr
incubation inblocking solution (1%BSA/PBS, 100Lperwell) at RT.Anti-HER2
antibody (rabbit polyclonal anti-erbB-2/Her-2 used at 2 g/mL; Upstate Bio-
technology) was added in triplicate wells (100 L per well) and incubated for
1 hr at RT, followed by aspiration and washing 3 times with PBS before 1 hr
incubation at RTwithHRP-conjugated secondary antibody at 1:2,000 dilution.
After aspirating secondary antibodies and washing the wells twice with PBS
and oncewith distilledwater, the platewas blotted dry and TMB solutionwas
added to eachwell. The plates were incubatedwith substrate for30min (or
until the blue color development) in the dark, and the reaction was stopped
by adding 100 L per well 1N HCl. Absorbances were measured at 450 nm in
a SpectraMaxM2platereader (Molecular Devices Corp.). To determinemouse
serum antibody titer, 96-well plates were coated with HerPBK10 (4 g per
well) in coating buffer (50 mM Na carbonate, pH 9.6) at 4 °C overnight. The
next day, wells were washed with 0.05% Tween/PBS and blocked with 5%
BSA/PBS for 2 hr at RT. Sera were diluted at 1:10, 1:100, 1:1,000, 1:10,000, and
1:50,000 ratios in 1% BSA/PBS and incubated in separate triplicate wells for 2
hr at RT. After washing to remove free antibody, wells were incubated 2 hr
with HRP-conjugated anti-mouse IgG (1:2,000) at RT, then processed for
measuring enzyme activity as described earlier.
In Vivo Studies. Female nude mice (6–8 wk) received bilateral flank injections
of 1  107 MDA-MB-435 human breast cancer cells, after which tumors of
250–300 mm3 were established within 3–4 wk. To obtain real-time imaging
of corrole conjugates during systemic delivery, mice received a single i.v.
injection of S2Ga or HerPBK10-S2Ga (15 nmol) and were imaged using a
real-time in vivo fluorescence image acquisition system developed by D.L.F.
(35). A 442 nm laser light was used for the excitation of corrole conjugates,
delivered onto the mice through mirrors, enabling uniform excitation of the
specimen by scattering the laser light via a 90% transmission broadband
diffuser. The emitted light from the mice was imaged by collection using a
telecentric lens (MELLES GRIOT, InvaritarTM 59LGL428 and 59LGG950, work-
ingdistance: 25.7mm, depthof field: 81.5mm,NA: 0.24), andpassing through
standard interference filters (Chroma, 620 nm 40 nm) before arriving onto
a cooled CCD camera (Princeton Instruments, PIXIS 400) located on top of the
light-tight imaging chamber. To test for therapeutic efficacy, mice began
receivingdaily tail vein injections after tumor establishment for 7 days of S2Ga
alone or HerGa (each at 0.008 mg/kg corrole concentration). Control mice
received HerPBK10 alone (at the equivalent concentration of protein in
HerGa), doxorubicin (at indicateddoses anddelivery routes), or vehicle (saline)
alone. Tumor volumesweremeasuredusing calipers for up to25days after the
final injection, after which mice were euthanized and tissues were harvested
for histological assessment [n  5–9 tumors per treatment; group numbers
based on power analysis of similar established studies (36)]. For immune
studies, blood from female 6- to 8-week-old C57BL/6 mice was collected
before administering a single s.c. injection each of HerPBK10 (0.05 or 0.5
mg/kg) or Ad5 (1.2 109 pfu), thenmice were bled every 7 days up to 35 days
after initial antigen inoculation. Themice received a second inoculationof the
same antigens on day 21. Blood was collected in serum separating tubes and
centrifuged at 1,000  g for 10 min to isolate the serum, which was assessed
for neutralizing antibody formation by ELISA as described earlier and for
receptor binding neutralization by cell attachment, as described in Cell At-
tachment Assay.
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Immunohistochemistry of Heart Specimens. Cross-sections (5 m thickness) of
the mid-ventricle areas of paraffin embedded hearts were prepared by AML
Labs. Specimens were deparaffinized and rehydrated by washing slides with
xylene 3 times 10min each, followed by a sequential 3min rinse each in 100%,
90%, 80%, then 70% ethanol. The slides were rinsed 3 times, 2 min each with
distilled water, then kept in 0.3% cold methanol for 30 min, followed by
washingwith PBS 3 times for 2min. The slides were warmed in 10mM citrate,
pH 6.0 in a 95 °Cwater bath for 30min, then cooled for 20min and rinsedwith
PBS 3 times for 2 min each. The slides were then blocked in 1% BSA/PBS for 1
hr at RT, followedby incubationwithmouse cardiacmyosin antibody (Abcam,
Inc.) at 1:100 dilution at 4 °C overnight. Next day, the slides were washed 3
times with PBS, followed by incubation with FITC-conjugated anti-mouse
antibody (Chemicon International, Inc.) at 1:300 dilution for 1 hr at RT. The
slides were washed 3 times with PBS and rinsed in water, then mounted with
ProLong Antifade kit (Molecular Probes, Invitrogen).
Cell Attachment Assay. To assess the effect of immune sera on HerPBK10
binding to target cells, separate wells in 96-well plates were coated with
HerPBK10 at 4 g per well by overnight incubation at 4 °C, followed by PBS
wash to remove free protein and blocking with 5% BSA/PBS for 2 hr at RT.
Meanwhile, MDA-MB-435 cells detached from dishes by 2 mM EDTA/PBS
followed by PBS wash were suspended in either complete media (containing
10% bovine serum), sera from immunocompetent mice previously inoculated
with antigens as described in Fig. 4A (collected on day 35), or preimmune sera
from the samemice, and added to separate triplicatewells (at 2 104 cells per
well) of the HerPBK10-coated plates. To verify the relative level of cell attach-
ment through HER, separate cells were preincubated with recombinant
heregulin ligand, or Her, at the indicated molar ratios of Her:HerPBK10 in
medium without mouse serum for 30 min with agitation, then plated on
HerPBK10-coated plates. The cells were allowed to attach at 37 °C in CO2
incubators for 1 hr, followed by aspiration of unattached cells, PBS wash, and
crystal violet assay to evaluate the relative number of attached cells. For the
crystal violet assay, the PBS was aspirated from the wells and replaced with
0.1% crystal violet in 10% ethanol per well. The plate was stained for 15 min
at RT, then the stain aspirated and wells washed thoroughly 4 times with 0.2
mL of PBS. The crystal violet was extracted from the cells with 95% ethanol.
The optical density (OD) of the samples were detected at 590 nm using a
SpectraMax M2 plate reader (Molecular Devices).
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